Credit Suisse Group upgraded shares of IPSEN S A/S (OTCMKTS:IPSEY) from an underperform rating to a neutral rating in a report issued on Tuesday, The Fly reports.
Other equities analysts also recently issued reports about the stock. Jefferies Financial Group downgraded shares of IPSEN S A/S from a buy rating to a hold rating in a report on Thursday, January 9th. Barclays downgraded shares of IPSEN S A/S from an overweight rating to an equal weight rating in a report on Monday, December 9th. Finally, JPMorgan Chase & Co. downgraded shares of IPSEN S A/S from a neutral rating to an underweight rating in a report on Sunday, January 5th. One analyst has rated the stock with a sell rating and six have given a hold rating to the stock. IPSEN S A/S has an average rating of Hold.
Shares of OTCMKTS:IPSEY opened at $18.21 on Tuesday. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of 10.47, a PEG ratio of 0.62 and a beta of 0.52. IPSEN S A/S has a 12 month low of $17.20 and a 12 month high of $35.97. The firm’s 50-day moving average is $20.61 and its 200 day moving average is $24.23.
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.